GeneReach Biotechnology Corp. (TPEX:4171)

Market Cap	918.26M -12.7%
Revenue (ttm)	238.08M +6.1%
Net Income	-43.09M
EPS	-0.76
Shares Out	56.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,216
Open	16.05
Previous Close	16.15
Day's Range	16.05 - 16.20
52-Week Range	16.05 - 26.90
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About GeneReach Biotechnology

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco Nucleic Acid Extraction Reagents, IQ REAL Quantitative System, and IQ20...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4171

Financial Performance

In 2025, GeneReach Biotechnology's revenue was 232.74 million, an increase of 12.71% compared to the previous year's 206.49 million. Losses were -110.28 million, -7.12% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 15, 2026

Data Sources Report a data error